 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DURHAM, N.C., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at...

Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

Humacyte, Inc. (NASDAQ:HUMA  Free Report)  Equities research analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for shares of Humacyte in a report issued on...

FY2024 Earnings Estimate for Humacyte, Inc. Issued By Cantor Fitzgerald (NASDAQ:HUMA)

-- Single-arm clinical trial was a success and showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks -- -- BLA...

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel  (HAV ) in Treatment of Patients with Vascular Trauma

-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage-DURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE...

Results From Mayo Clinic Clinical Study of Humacyte s Human Acellular Vessel  (HAV ) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma RepairDURHAM, N.C., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a...

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel  (HAV ) Tuesday, September 12, 2023 at 8:00 AM ET

Humacyte (NASDAQ:HUMA  Get Free Report)s stock had its overweight rating reaffirmed by analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports...

Cantor Fitzgerald Reiterates "Overweight" Rating for Humacyte (NASDAQ:HUMA)

Cantor Fitzgerald reiterated their overweight rating on shares of Humacyte (NASDAQ:HUMA  Free Report) in a report released on Thursday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the stock. A number of other analysts have also commented on HUMA. Piper ...

Humacyte (NASDAQ:HUMA) Earns "Overweight" Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Humacyte (NASDAQ:HUMA  Free Report) in a report released on Thursday, Benzinga reports. The brokerage currently has a $6.00...

Humacyte (NASDAQ:HUMA) Stock Rating Reaffirmed by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA  Get Free Report) CEO Laura E. Niklason sold 602,443 shares of Humacyte stock in a transaction on Monday, August 21st. The shares were sold at an average price of $3.39, for a total transaction of $2,042,281.77. Following the completion of the transaction, the ...

Humacyte, Inc. (NASDAQ:HUMA) CEO Sells $2,042,281.77 in Stock

Humacyte, Inc. (NASDAQ:HUMA  Get Free Report) Director Brady W. Dougan sold 626,979 shares of Humacyte stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $3.57, for a total value of $2,238,315.03. Following the sale, the director now directly owns 8,...

Insider Selling: Humacyte, Inc. (NASDAQ:HUMA) Director Sells $2,238,315.03 in Stock

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Watchers	2,581
52-Wk Low	$1.96
52-Wk High	$5.60

Market Cap	$297.89M
Volume (M)	355,938.00
52-Wk High	$5.60
52-Wk Low	$1.96

HUMA Humacyte Inc

About

Feed

News

Sentiment

Earnings

Fundamentals